trial failure
Biogen halts Tysabri trial after failure in acute ischemic stroke
February 8, 2018Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure
Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …
FDA halts Bellicum trial over brain disease in participants, shares crash 48%
February 1, 2018Research and Development Bellicum Pharmaceuticals, FDA, encephalopathy, pharma, trial failure
Texas-based clinical-stage company Bellicum Pharmaceuticals has taken a massive stock hit after the FDA put a hold on its trials …
Galectin Therapeutics’ share value plummets by half after NASH drug failure
December 6, 2017Research and Development Galectin Therapeutics, nash, pharma, trial failure
Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …
Stem cell therapy fails to improve symptoms of peripheral artery disease
November 16, 2017Research and Development Stem cells, peripheral artery disease, pharma, stem cell therapy, trial failure
A new study has revealed that a promising stem cell therapy failed to improve ability to walk in patients with …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
September 14, 2017Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
AZ “disappointment” at heart drug failure
October 5, 2016Research and Development AZ, AstraZeneca, trial failure
AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals
June 15, 2016Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure
Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
